CFC-FREE ALBUTEROL MDI STUDIES SHOULD TRY TO ACHIEVE DOSE RESPONSE FOR COMPARABILITY -- FDA's JENKINS; ACUTE ASTHMA AND PEDIATRIC STUDIES SUGGESTED
Executive Summary
Chlorofluorocarbon-free albuterol metered-dose inhaler future studies should strive for an adequate dose response to show comparability to existing products, FDA Division of Pulmonary Drug Products Director John Jenkins, MD, said at the Pulmonary-Allergy Drugs Advisory Committee meeting March 29.